AnaptysBio (NASDAQ:ANAB – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare AnaptysBio to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.
Profitability
This table compares AnaptysBio and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AnaptysBio | 82.37% | 112.00% | 2.20% |
| AnaptysBio Competitors | -12,346.73% | -197.60% | -30.56% |
Risk & Volatility
AnaptysBio has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, AnaptysBio’s rivals have a beta of 1.10, meaning that their average stock price is 10% more volatile than the S&P 500.
Earnings and Valuation
This table compares AnaptysBio and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| AnaptysBio | $234.60 million | -$13.23 million | 8.65 |
| AnaptysBio Competitors | $715.93 million | $12.70 million | -15.10 |
AnaptysBio’s rivals have higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 31.5% of AnaptysBio shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for AnaptysBio and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AnaptysBio | 1 | 3 | 12 | 0 | 2.69 |
| AnaptysBio Competitors | 9839 | 15124 | 45438 | 1588 | 2.54 |
AnaptysBio currently has a consensus price target of $75.67, suggesting a potential upside of 62.90%. As a group, “Biotechnology” companies have a potential upside of 103.25%. Given AnaptysBio’s rivals higher probable upside, analysts clearly believe AnaptysBio has less favorable growth aspects than its rivals.
Summary
AnaptysBio beats its rivals on 7 of the 13 factors compared.
AnaptysBio Company Profile
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
